These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33997320)

  • 1. Prognostic utility of pretreatment neutrophil-lymphocyte ratio in survival outcomes in localized non-small cell lung cancer patients treated with stereotactic body radiotherapy: Selection of an ideal clinical cutoff point.
    Kotha NV; Cherry DR; Bryant AK; Nalawade V; Stewart TF; Rose BS
    Clin Transl Radiat Oncol; 2021 May; 28():133-140. PubMed ID: 33997320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Utility of Pretreatment Neutrophil-Lymphocyte Ratio in Advanced Larynx Cancer.
    Kotha NV; Voora RS; Qian AS; Kumar A; Qiao EM; Stewart TF; Rose BS; Orosco RK
    Biomark Insights; 2021; 16():11772719211049848. PubMed ID: 34658619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of neutrophil-lymphocyte ratio with survival in peripheral early-stage non-small cell lung cancer after stereotactic body radiation therapy.
    Huang K; Prasad S; Ma SJ; Yu H; Iovoli AJ; Farrugia MK; Dexter EU; Demmy TL; Malik NK; Singh AK
    BMC Cancer; 2023 Mar; 23(1):254. PubMed ID: 36932396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Post-radiation neutrophil-to-lymphocyte ratio is a prognostic marker in patients with localized pancreatic adenocarcinoma treated with anti-PD-1 antibody and stereotactic body radiation therapy.
    Reddy AV; Hill CS; Sehgal S; Zheng L; He J; Laheru DA; Jesus-Acosta A; Herman JM; Meyer J; Narang AK
    Radiat Oncol J; 2022 Jun; 40(2):111-119. PubMed ID: 35796114
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Pre-Treatment NLR and Other Hematologic Biomarkers on the Outcomes of Early-Stage Non-Small-Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.
    Aduquaye M; Dube S; Bashir B; Chowdhury A; Ahmed N; Leylek A; Kim J; Lambert P; Bucher O; Hunter W; Sivananthan G; Koul R; Rathod S
    Curr Oncol; 2022 Jan; 29(1):193-208. PubMed ID: 35049693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-lymphocyte ratio and platelet-lymphocyte ratio associations with heart and body dose and their effects on patient outcomes in locally advanced non-small cell lung cancer treated with definitive radiotherapy.
    Xia WY; Zhu XR; Feng W; Liu J; Wang JM; Lv CX; Zhang Q; Yu W; Cai XW; Fu XL
    Transl Lung Cancer Res; 2020 Oct; 9(5):1996-2007. PubMed ID: 33209619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study.
    Piao MN; Xie J; Jin MM; Ma XT; Dou Z; Wang JP; Li JL
    Transl Lung Cancer Res; 2024 Aug; 13(8):1950-1963. PubMed ID: 39263027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of pretreatment circulating neutrophils, monocytes, and lymphocytes on outcomes in lung stereotactic body radiotherapy.
    Giuliani M; Sampson LR; Wong O; Gay J; Le LW; Cho BC; Brade A; Sun A; Bezjak A; Hope AJ
    Curr Oncol; 2016 Aug; 23(4):e362-8. PubMed ID: 27536185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic Inflammation Biomarkers Predict Survival in Patients of Early Stage Non-Small Cell Lung Cancer Treated With Stereotactic Ablative Radiotherapy - A Single Center Experience.
    Luo H; Ge H; Cui Y; Zhang J; Fan R; Zheng A; Zheng X; Sun Y
    J Cancer; 2018; 9(1):182-188. PubMed ID: 29290784
    [No Abstract]   [Full Text] [Related]  

  • 10. Pretreatment Neutrophil-to-Lymphocyte Ratio (NLR) May Predict the Outcomes of Advanced Non-small-cell Lung Cancer (NSCLC) Patients Treated With Immune Checkpoint Inhibitors (ICIs).
    Li Y; Zhang Z; Hu Y; Yan X; Song Q; Wang G; Chen R; Jiao S; Wang J
    Front Oncol; 2020; 10():654. PubMed ID: 32656072
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of systemic inflammation biomarkers on overall survival after lung cancer radiotherapy: a single-center large-cohort study.
    Abravan A; Salem A; Price G; Faivre-Finn C; van Herk M
    Acta Oncol; 2022 Feb; 61(2):163-171. PubMed ID: 34979860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High neutrophil-to-lymphocyte ratio following stereotactic body radiation therapy is associated with poor clinical outcomes in patients with borderline resectable and locally advanced pancreatic cancer.
    Reddy AV; Hill CS; Sehgal S; He J; Zheng L; Herman JM; Meyer J; Narang AK
    J Gastrointest Oncol; 2022 Feb; 13(1):368-379. PubMed ID: 35284125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationships between longitudinal neutrophil to lymphocyte ratios, body weight changes, and overall survival in patients with non-small cell lung cancer.
    Derman BA; Macklis JN; Azeem MS; Sayidine S; Basu S; Batus M; Esmail F; Borgia JA; Bonomi P; Fidler MJ
    BMC Cancer; 2017 Feb; 17(1):141. PubMed ID: 28209123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic impact of neutrophil to lymphocyte ratio in advanced non-small cell lung cancer patients treated with EGFR TKI.
    Phan TT; Ho TT; Nguyen HT; Nguyen HT; Tran TB; Nguyen ST
    Int J Gen Med; 2018; 11():423-430. PubMed ID: 30510441
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Pre- and Posttreatment Neutrophil-Lymphocyte Ratio With Recurrence and Mortality in Locally Advanced Non-Small Cell Lung Cancer.
    Sebastian NT; Raj R; Prasad R; Barney C; Brownstein J; Grecula J; Haglund K; Xu-Welliver M; Williams TM; Bazan JG
    Front Oncol; 2020; 10():598873. PubMed ID: 33251151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.